课题基金 / 基金详情

A randomised controlled trial to test the clinical and cost-effectiveness of primary care referral to a commercial weight loss provider.

A randomised controlled trial to test the clinical and cost-effectiveness of primary care referral to a commercial weight loss provider.
一项随机对照试验,旨在测试初级保健转介给商业减肥提供商的临床和成本效益。
批准号:
MC_EX_MR/J000493/1
负责人:
Amy Ahern
金额:
$115.54万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2012
资助国家:
英国
项目状态:
已结题
起止时间:
2012 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Overweight and obesity is a serious public health issue due to its high prevalence and association with illnesses, such as Type II diabetes, heart disease and cancer. Early treatment and prevention are important if we are to reduce the health problems associated with excess weight, but there are few treatments available through the National Health Service (NHS) and those that are available can be very costly when we consider the number of people requiring treatment. It is in the interests of the NHS to offer (cost-effective) weight loss treatment options, as they spend £4.2 billion each year on treating illness related to overweight and obesity. The cost to the wider community is estimated at £16 billion. This study seeks to examine one of the treatment options currently available on the NHS - referral to a commercial weight loss treatment provider - and to establish whether this treatment option is cost-effective in helping people to lose weight and keep it off. Previous research has shown that referring a patient for 12 sessions with a commercial weight loss provider can produce an amount of weight loss which has significant health benefits. These referral packages are offered to the NHS at a discounted price, however no studies have formally evaluated the cost-effectiveness of this approach. This study will examine whether the money spent on treatment is worthwhile when we consider the effect of improved health for patients and also potential cost savings on treatments for weight-related illness. But weight regain is common after weight loss treatment stops and it may be that 12 weeks is not long enough to develop long term changes in behaviour. It is not hard to imagine that a 12 month referral could lead to greater weight loss and more long term changes than a 12 week programme, and that this could mean less weight regain. However, the likely increased effect will come at a higher cost, leaving the question 'What is the more cost-effective option?'. This is precisely what this study seeks to examine. We also want to uderstand more about the patient experience of weight loss treatment. Previous research has shown that many adults with overweight and obesity do not consider this to be a medical problem and this may influence their attitudes to receiving treatment through the NHS. By improving our understanding of attitudes and experience of treatment, we can improve the way weight management is provided by the NHS.In our trial, 1200 adults with overweight and obesity will be identified by their GP and recruited by the research team. The research team will randomly assign participants to one of three treatment groups - a 12 session referral to a commercial provider, a 12 month referral to a commercial provider, or a 'brief intervention' (standard information about how to lose weight and weighing at follow up). We will follow participants up at 3 months, 12 months and 24 months (1 year after treatment has finished) to compare the amount of weight lost by participants in each group. We will also look at how many participants in each group lose an amount of weight that is associated with significant health improvements. We will use this and other data collected during the trial to examine which treatment option offers the best value for money. This will be examined over the short term (the duration of the trial) and the longer term, using long term modelling of anticipated health changes and associated costs. We will also interview a subset of participants to gain a more holistic view of the patient experience and to explore their attitudes to weight loss treatment and NHS-commercial partnerships.This research will provide important information to GPs and NHS treatment commissioners about which treatment option is most effective and which offers best value for money. Trial results and findings from interviews will help inform future decisions about NHS-commercial partnership
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.3399/bjgp15x684409
发表时间: 2015-04
期刊: The British journal of general practice : the journal of the Royal College of General Practitioners
影响因子: --
作者: [Allen JT, Cohn SR, Ahern AL]
通讯作者: Ahern AL
DOI: 10.1186/s12889-024-18134-4
发表时间: 2024-03-12
期刊: BMC PUBLIC HEALTH
影响因子: 4.5
作者: [Bates,Sarah, Breeze,Penny, Brennan,Alan]
通讯作者: Brennan,Alan
DOI: 10.3399/bjgp16x684337
发表时间: 2016-04
期刊: The British journal of general practice : the journal of the Royal College of General Practitioners
影响因子: --
作者: [Ahern AL, Aveyard P, Boyland EJ, Halford JC, Jebb SA, WRAP trial team]
通讯作者: WRAP trial team
DOI: 10.1016/s0140-6736(17)30647-5
发表时间: 2017-06-03
期刊: Lancet (London, England)
影响因子: --
作者: [Ahern AL, Wheeler GM, Aveyard P, Boyland EJ, Halford JCG, Mander AP, Woolston J, Thomson AM, Tsiountsioura M, Cole D, Mead BR, Irvine L, Turner D, Suhrcke M, Pimpin L, Retat L, Jaccard A, Webber L, Cohn SR, Jebb SA]
通讯作者: Jebb SA
6
    国内基金
    海外基金
    槲皮素控释系统调控Mettl3/Per1修复氧化应激损伤促牙周炎骨再生及机制研究
    • 批准号:
      82370921
    • 项目类别:
      面上项目
    • 资助金额:
      48.00万元
    • 批准年份:
      2023
    • 负责人:
      徐袁瑾
    • 依托单位:
    肿瘤翻译调控蛋白调控大肠癌细胞转移能力的信号机制研究
    • 批准号:
      81000952
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      20.0万元
    • 批准年份:
      2010
    • 负责人:
      马强
    • 依托单位:
    多肽树状物为载体的抗癌前体药物的合成和研究
    植物病毒壳体"智能"纳米载体靶向肿瘤细胞的研究
    • 批准号:
      30973685
    • 项目类别:
      面上项目
    • 资助金额:
      35.0万元
    • 批准年份:
      2009
    • 负责人:
      曾庆冰
    • 依托单位: